Owens & Minor misses Q2 earnings estimates as it prepares for divestiture

Owens & Minor (OMI) reported Q2 adjusted earnings per share of $0.26, missing analyst estimates of $0.29, which led to a 1.83% after-hours stock decline. This quarter was marked by significant one-time expenses, including an $80 million transaction breakage fee, as the company progresses with the divestiture of its Products & Healthcare Services segment to transition into a pure-play Patient Direct business. Despite the overall earnings miss, continuing operations, primarily the Patient Direct segment, demonstrated resilience with revenue increasing 3.3% to $681.9 million and adjusted EBITDA rising to $96.6 million, with OMI planning to issue a 2025 financial outlook for this focused segment.

Analysis

Owens & Minor (OMI) reported second-quarter results that reflect a company in a significant strategic transition, leading to mixed signals for the market. The headline adjusted EPS of $0.26 missed the consensus estimate of $0.29, triggering a 1.83% after-hours stock decline. However, these earnings were heavily impacted by substantial one-time expenses, including an $80 million transaction breakage fee and $18.3 million in financing fees, which obscure the underlying operational performance. The central development is the company's move to divest its Products & Healthcare Services segment to pivot into a pure-play Patient Direct business. The performance of these continuing operations, which will form the core of the future company, showed resilience and growth. Revenue from this segment increased 3.3% year-over-year to $681.9 million, and its adjusted EBITDA grew to $96.6 million from $91.1 million. This suggests the go-forward business possesses solid fundamentals, a point underscored by management's confidence in its ability to capitalize on favorable demographic trends. The classification of the legacy segment as discontinued operations marks the final stages of this strategic shift, but the lack of immediate 2025 guidance creates a near-term information vacuum, with the upcoming earnings call poised to be a critical event for clarifying the firm's future earnings power.

Key Decisions for Investors

• Investors should look past the headline Q2 earnings miss, as it was distorted by significant one-time costs, and instead concentrate on the fundamental performance of the continuing Patient Direct segment, which demonstrated 3.3% revenue growth.
• The upcoming 2025 financial outlook, to be released during the earnings call, is a key catalyst that will provide the first clear view of the streamlined company's earnings potential and should be monitored closely before adjusting positions.
• Consider the execution risk associated with the final divestiture of the Products & Healthcare Services segment, as the timing and proceeds from the sale will be crucial for the company's balance sheet and future capital allocation.
• Evaluate OMI not on its historical performance but on its potential valuation as a focused, higher-growth Patient Direct entity, pending confirmation of margins and growth targets in the forthcoming guidance.